Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1

Head and Neck

Volumn 31, Issue 12, 2009, Pages 1624-1633

  Zhou, Shui Hong ^a   Fan, Jun ^b   Chen, Xiao Ming ^b   Cheng, Ke Jia ^a   Wang, Shen Qing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antisense oligonucleotide; Glucose transporter 1; Glucose uptake; Laryngeal carcinoma; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUCOSE TRANSPORTER 1; RECOMBINANT PROTEIN;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE SEQUENCE; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; HEP 2 CELL; HUMAN; HUMAN CELL; LARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LARYNGEAL NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PLASMIDS; POLYMERASE CHAIN REACTION; PROBABILITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 72449129516     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21137     Document Type: Article

References (22)

1. Warburg O. On the origin of cancer cells. Science (Washington DC) 1956,123:309-314.
2. Wu X, Freeze HH. GLUT-14, a duplicon of GLUT-3, is specifically expressed in testis as alternative splice forms. Genomics 2002;80:553-557. (Pubitemid 36062642)
3. Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-876.
4. Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004;136:548-556. (Pubitemid 39186566)
5. 18F] fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-17.
6. Vleugel MM, Greijer AE, Shvarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005;58:172-177. (Pubitemid 40193803)
7. 18FFDG metabolic imaging in diagnosis and treatment of head and neck tumors and its mechanism study [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87:109-113.
8. Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1, 3 in the head and neck carcinoma: the correlation the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 2008;70:189-194.
9. Jason TL, Berg RW, Vincent MD, Koropatnick J. Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs. Gene Expr 2007;13:227-239. (Pubitemid 47024154)
10. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12: 1543-1568.
11. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 2003;82:11-16.
12. Kojima H, Iida M, Yaguchi Y, et al. Enhancement of cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006;132:682-685. (Pubitemid 43927048)
13. Nakashima T, Hudson JM, Clayman GL. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck 2000;22:483-488. (Pubitemid 30483057)
14. Faust RA, Tawfic S, Davis AT, Bubash LA, Ahmed K. Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 2000;22: 341-346. (Pubitemid 30413298)
15. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head neck 2003; 25:67-73. (Pubitemid 36005333)
16. Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 2000;154:175-182. (Pubitemid 30259224)
17. Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. Life Sci 2000;67:2117-2124.
18. Chen CP, Li XX, Zhang LR, et al. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 andMCF-7 Cells. Bioconjug Chem 2002;13:525-529.
19. Rudrappa SG, Humphrey BD. Energy metabolism in developing chicken lymphocytes is altered during the embryonic to posthatch transition. J Nutr 2007;137: 427-432.
20. Mercatante D, Kole R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 2000;85:237-243. (Pubitemid 30160793)
21. Flynn J, Berg RW, Wong T, et al. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 2006;5:1423-1433. (Pubitemid 44070478)
22. Liu Z, Yuan J, Yanagawa B, Qiu D, McManus BM, Yang D. Coxsackievirus-induced myocarditis: new trends in treatment. Expert Rev Anti Infect Ther 2005; 3:641-650. (Pubitemid 41223223)